Quarterly report [Sections 13 or 15(d)]

WARRANTS TO PURCHASE COMMON STOCK

v3.26.3
WARRANTS TO PURCHASE COMMON STOCK
 9 Months Ended
Sep. 30, 2026
Warrants To Purchase Common Stock  
WARRANTS TO PURCHASE COMMON STOCK

NOTE 14 – WARRANTS TO PURCHASE COMMON STOCK

 

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at September 30, 2026:

 

Exercise     Number     Expiration  
Price     Outstanding     Date  
$ 0.001       615,025 (1)      December 2030  
$ 1,056.00       4,585       April 2029  
$ 1,056.00       2,782       April 2029  
$ 1,056.00       2,172       April 2029  
$ 1,056.00       10,884       April 2029  
$ 1,600.00       36       October 2028  
$ 2,720.00       5,758       December 2028  
$ 3,200.00       22       August 2028  
          641,264          

 

(1)   Represents prefunded warrants.

 

During the nine months ended September 30, 2025, 13,666 warrants with an exercise price of $1,056 became exercisable, 5,758 warrants with an exercise price of $1,776 became exercisable upon FDA acceptance of our NDA filing, and 1 warrant with an exercise price of $364,800 expired.